首页|中药单体及复方治疗原发性肝癌的药效及机制研究进展

中药单体及复方治疗原发性肝癌的药效及机制研究进展

扫码查看
原发性肝癌是常见的恶性肿瘤之一,其临床治疗现状无法令人满意.中医药是癌症综合治疗的重要组成部分,对原发性肝癌的治疗具有独特优势.本文检索近5年中药单体及复方治疗原发性肝癌主要组织学亚型群(HCC)的中英文文献.基于化合物分类,从黄酮类、萜类、多酚类介绍了中药单体在HCC治疗中的新进展,为中药单体、复方治疗HCC提供参考.基于辨证论治,从疏肝健脾、益气活血、解毒抗癌、软坚散结、扶正消积等方面介绍了中药复方在HCC治疗中的新进展,意在为HCC治疗提供更宽广的前景和思路,为基于物质基础深入研究中医药治疗HCC药效作用与机制提供参考.
Advances in the Efficacy and Mechanisms of Chinese Herbal Medicine Compounds and Monomers in the Treatment of Primary Liver Cancer
Primary liver cancer is one of the most common malignant tumors,and the current clinical treatments remain unsatisfactory.Traditional Chinese Medicine(TCM)is an integral part of comprehensive cancer therapy and has unique advantages in treating primary liver cancer.This paper reviews Chinese and English literature from the past five years on the use of Chinese herbal medicine compounds and monomers in the treatment of primary liver cancer.The review categorizes compounds into flavonoids,terpenes,and polyphenols to discuss the latest advancements in TCM monomers for primary liver cancer treatment,providing references for the transition from monomer to compound therapy.Based on the principles of syndrome differentiation and treatment,the paper also discusses new developments in Chinese herbl medicine compounds for primary liver cancer treatment,focusing on strategies such as"soothing the liver and strengthening the spleen,""tonifying qi and activating blood circulation,""detoxifying and anticancer,""softening hardness and dissipating nodules,"and"supporting the healthy qi and eliminating accumulation."The aim is to provide broader prospects and ideas for the treatment of hepatocellular carcinoma(HCC)and to offer references for further research into the efficacy and mechanisms of TCM in HCC treatment based on material foundations.

Primary liver cancerTCM compoundsTCM monomersEfficacy mechanisms

吴宏昊、王浩艺、成扬

展开 >

上海中医药大学附属曙光医院,上海 201203

上海中医药大学肝肾疾病病证教育部重点实验室,上海 201203

原发性肝癌 中药复方 中药单体 药效机制

2025

中医药学报
中华中医药学会,黑龙江中医药大学

中医药学报

影响因子:1.169
ISSN:1002-2392
年,卷(期):2025.53(1)